Press Release: Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Dow Jones11-05
 EQUITY                     $   17,307        $     19,185 
                    =========  =======           ========= 
 
(* Represents an amount lower than $1 USD.) 
 
 
 
                           NUVECTIS PHARMA, INC. 
                     CONDENSED STATEMENTS OF OPERATIONS 
           (USD in thousands, except per share and share amounts) 
                                (unaudited) 
 
                       Three Months Ended      Nine Months Ended September 
                          September 30                      30 
                   --------------------------  ---------------------------- 
                      2024          2023          2024          2023 
                   -----------   -----------   -----------   ----------- 
OPERATING 
EXPENSES: 
  Research and 
   development     $     2,819   $     4,486   $     8,422   $    11,115 
  General and 
   administrative        1,540         1,672         4,976         4,916 
                    ----------    ----------    ----------    ---------- 
 
OPERATING LOSS          (4,359)       (6,158)      (13,398)      (16,031) 
                    ----------    ----------    ----------    ---------- 
  Finance income           206           277           646           393 
                    ----------    ----------    ----------    ---------- 
 
NET LOSS           $    (4,153)  $    (5,881)  $   (12,752)  $   (15,638) 
                    ==========    ==========    ==========    ========== 
NET LOSS 
 ATTRIBUTABLE TO 
 COMMON 
 STOCKHOLDERS      $    (4,153)  $    (5,881)  $   (12,752)  $   (15,638) 
                    ----------    ----------    ----------    ---------- 
BASIC AND DILUTED 
 NET LOSS PER 
 COMMON STOCK 
 OUTSTANDING       $     (0.24)  $     (0.37)  $     (0.75)  $     (1.02) 
                    ==========    ==========    ==========    ========== 
Basic and diluted 
 weighted average 
 number of common 
 stock 
 outstanding        17,230,559    16,104,446    16,898,040    15,341,685 
                    ==========    ==========    ==========    ==========

(END) Dow Jones Newswires

November 05, 2024 07:00 ET (12:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment